Patent ID: 8685404

Claim:
A method for treating cognitive or neuropsychiatric impairment induced by substance addiction, comprising selecting a subject with a substance addiction; and administering to the subject a therapeutically effective amount of a Major Histocompatibility Complex (MHC) molecule comprising covalently linked first, second and third domains, wherein: the first domain is an MHC class II Î²1 domain and the second domain is an MHC Class II Î±1 domain, wherein the amino terminus of the Î±1 domain is covalently linked to the carboxy terminus of the Î²1 domain, wherein the MHC molecule does not comprise an MHC class II Î±2 domain or an MHC Class II Î²2 domain, and wherein the third domain is covalently linked to the first domain, wherein the third domain comprises an antigenic determinant, wherein the antigenic determinant is MOG 35-55; thereby treating the cognitive or neuropsychiatric impairment in the subject, wherein the subject does not have multiple sclerosis or a stroke.